Literature DB >> 19421009

Downregulation of LRIG2 expression by RNA interference inhibits glioblastoma cell (GL15) growth, causes cell cycle redistribution, increases cell apoptosis and enhances cell adhesion and invasion in vitro.

Baofeng Wang1, Lin Han, Rudong Chen, Mingjun Cai, Fuxin Han, Ting Lei, Dongsheng Guo.   

Abstract

The leucine-rich and immunoglobulin-like domains (LRIG) gene family contains LRIG1, 2 and 3. LRIG1 is a negative regulator of EGFR, but little is known about the function of LRIG2. To determine the role of LRIG2 in the progression of glioma, we performed RNA interference-mediated knockdown of LRIG2 in a human glioma cell line (GL15). Downregulation of LRIG2 expression resulted in: rapid EGF-mediated loss of EGFR; decreased proliferation; G(0)/G(1) arrest; increased spontaneous apoptosis; enhanced cell adhesion and increased invasion capability of GL15 cells in vitro. These findings indicate that LRIG2 possesses distinct functions compared with LRIG1 and validate the attractiveness of LRIG2 as a target in glioma therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19421009     DOI: 10.4161/cbt.8.11.8375

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  20 in total

1.  Effects of RNAi-mediated gene silencing of LRIG1 on proliferation and invasion of glioma cells.

Authors:  Feng Mao; Baofeng Wang; Guifa Xi; Wei Sun; Huaqiu Zhang; Fei Ye; Dongsheng Guo; Ting Lei
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-04-20

2.  Effect of over-expressed LRIG3 on cell cycle and survival of glioma cells.

Authors:  Hongkuan Yang; Feng Mao; Huaqiu Zhang; Baofeng Wang; Feng Wan; Dongsheng Guo; Ting Lei
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-10-25

Review 3.  The LRIG family: enigmatic regulators of growth factor receptor signaling.

Authors:  Catalina Simion; Maria Elvira Cedano-Prieto; Colleen Sweeney
Journal:  Endocr Relat Cancer       Date:  2014-09-02       Impact factor: 5.678

Review 4.  Urofacial syndrome: a genetic and congenital disease of aberrant urinary bladder innervation.

Authors:  Adrian S Woolf; Helen M Stuart; Neil A Roberts; Edward A McKenzie; Emma N Hilton; William G Newman
Journal:  Pediatr Nephrol       Date:  2013-07-09       Impact factor: 3.714

5.  Association of expression of Leucine-rich repeats and immunoglobulin-like domains 2 gene with invasiveness of pituitary adenoma.

Authors:  Huaqiu Zhang; Qin Yan; Shutian Xu; Yibo Ou; Fei Ye; Baofeng Wang; Ting Lei; Dongsheng Guo
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-08-07

Review 6.  Genetics of human congenital urinary bladder disease.

Authors:  Adrian S Woolf; Helen M Stuart; William G Newman
Journal:  Pediatr Nephrol       Date:  2013-04-13       Impact factor: 3.714

7.  LRIG2 mutations cause urofacial syndrome.

Authors:  Helen M Stuart; Neil A Roberts; Berk Burgu; Sarah B Daly; Jill E Urquhart; Sanjeev Bhaskar; Jonathan E Dickerson; Murat Mermerkaya; Mesrur Selcuk Silay; Malcolm A Lewis; M Beatriz Orive Olondriz; Blanca Gener; Christian Beetz; Rita E Varga; Omer Gülpınar; Evren Süer; Tarkan Soygür; Zeynep B Ozçakar; Fatoş Yalçınkaya; Aslı Kavaz; Burcu Bulum; Adnan Gücük; Wyatt W Yue; Firat Erdogan; Andrew Berry; Neil A Hanley; Edward A McKenzie; Emma N Hilton; Adrian S Woolf; William G Newman
Journal:  Am J Hum Genet       Date:  2013-01-11       Impact factor: 11.025

8.  The negative regulation of miR-149-5p in melanoma cell survival and apoptosis by targeting LRIG2.

Authors:  Wenqi Chen; Jinhai Zhang; Huijuan Xu; Jie Dai; Xiaorong Zhang
Journal:  Am J Transl Res       Date:  2017-09-15       Impact factor: 4.060

Review 9.  LRIG and cancer prognosis.

Authors:  David Lindquist; Samuel Kvarnbrink; Roger Henriksson; Håkan Hedman
Journal:  Acta Oncol       Date:  2014-09-02       Impact factor: 4.089

10.  In vivo analysis of Lrig genes reveals redundant and independent functions in the inner ear.

Authors:  Tony Del Rio; Allison M Nishitani; Wei-Ming Yu; Lisa V Goodrich
Journal:  PLoS Genet       Date:  2013-09-26       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.